CHICAGO >> Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance ...

AstraZeneca's new breast cancer pill, Camizestrant, shows promising results. The drug delayed cancer progression by over six ...

Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding ...

By Julie Steenhuysen CHICAGO (Reuters) -Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at ...

Asandeutertinib is a derivative of Tagrisso designed to avoid certain toxic side effects in patients with EGFR-mutated NSCLC.

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

A new blood test-guided breast cancer treatment could more than half the risk of cancer progression in patients, researcher ...

A clinical trial found that women could switch drugs without waiting for scans showing cancer progression, which improved ...

Asad Haider, head of the healthcare business unit within Goldman Sachs Research, now forecasts the market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, to ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...